Bing

SEARCH HISTORY

Aeterna Zentaris Inc. appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt. Cash Collection is the best in the industry. At the end of 2014, its uncollected receivables totaled $583.0K ...
Bloomberg · 1 day ago
ARRIS Group, Inc. (NASDAQ:ARRS) as well as Pace plc jointly reported that they have decided that ARRIS will purchase Pace for aggregate stock and cash consideration of $2.1B (1.4 billion). The transaction will result in the formation of New ARRIS ...
streetwisereport.com · 4/23/2015
The government has set a floor price at Rs.254 per equity share for divestment of 5 percent of its stake in PFC, it had said in a stock exchange filing on Saturday. The government holds 72.80 percent equity in the company, while the stake sale is expected ...
Daijiworld · 7/27/2015
Aeterna Zentaris Inc. (AEZS,AEZ.TO) said Tuesday that it has received written scientific advice from the European Medicines Agency or "EMA" regarding the further development plan, including the study design, for the new confirmatory Phase 3 clinical study ...
Realtime Business News · 5/26/2015
Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor …
News-Medical · 6/15/2010
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. For more information, visit www.aezsinc.com. SOURCE Aeterna Zentaris Inc.
Stockhouse · 4/23/2015
The following stocks declined the most in After-Hours trade, as of 5: 05 p.m., April 10, 2013: Dehaier Medical Systems Limited (NASDAQ: DHRM) traded at $1.8, down -9.0 pct in after-hours on 3,660 traded shares. The company traded 3.87 pct above its …
Fx Pips · 4/11/2013
All companies selected are more than 42% off a 52-week high. The current AEZS share price is $1.47, or 57.4% off the 52-week high of $3.45. Down 39% over 12 months, AEterna Zentaris Inc. has a market cap of $45.61 million, and trades at a P/B of 5.80.
Guru Focus · 10/13/2013
Keryx Biopharmaceuticals Inc. (KERX) and Aeterna Zentaris Inc. (AEZS) reported the combined use of perifosine and the chemotherapy-drug capecitabine as a treatment for refractory advanced colorectal cancer didn’t meet a Phase 3 clinical trial’s …
The Wall Street Journal · ByCorrie Driebusch andDrew Fitzgerald · 4/2/2012
ZIMBABWE'S agro-ecological zones (AEZs or natural regions) have shifted drastically because of the devastating effects of climate change and global warming. Although the changes have not been officially adopted, major shifts have occurred in the drier ...
AllAfrica · 10/22/2012